Fibroblast growth factor receptor 3 amplified metastatic melanoma treated with erdafitinib Journal Article
| Authors: | Sarkisian, S.; McIntosh, A.; Nair, S.; Shoushtari, A. N.; Callahan, M. |
| Article Title: | Fibroblast growth factor receptor 3 amplified metastatic melanoma treated with erdafitinib |
| Abstract: | The treatment of metastatic melanoma has changed dramatically in the last decade with the introduction of immunotherapy and targeted therapy. A futile disease in the past is now treated with various options, resulting in improvement in progression-free and overall survivals, along with improvement in the quality of life. Having said that, the majority of patients with metastatic melanoma eventually succumb to the disease. Molecular profiling of each tumor in the advanced stage is standard of care now, as this would lead to individualized treatment options for each patient. Here, we present a rare case of fibroblast growth factor receptor 3 (FGFR 3) amplified metastatic melanoma, treated rather unconventionally with FGFR 3 inhibitor erdafitinib. |
| Keywords: | protein; immunotherapy; targeted therapy; expression; fgfr3; diffuse metastatic melanoma |
| Journal Title: | Cureus |
| Volume: | 12 |
| Issue: | 10 |
| ISSN: | 2168-8184 |
| Publisher: | Cureus Inc. |
| Date Published: | 2020-10-01 |
| Start Page: | e11231 |
| Language: | English |
| ACCESSION: | WOS:000583182900003 |
| DOI: | 10.7759/cureus.11231 |
| PROVIDER: | wos |
| PMCID: | PMC7704269 |
| PUBMED: | 33269159 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
197Callahan -
244Shoushtari
Related MSK Work